Network models of protein phosphorylation, acetylation, and ubiquitination connect metabolic and cell signaling pathways in lung cancer
Fig 4
EGFR signaling and glycolysis pathway interactions.
(A) Direct CFN connections between proteins in the EGFR signaling and glycolysis pathways and their PTMs that are significantly changed by erlotinib (median fold change in erlotinib-treated vs. control cells at least 2.25). (B) CFN connections between RTKs and SFKs and Glycoylsis and gluconeogenesis pathway proteins. (C, D) Sub-network from EGFR-glycolysis shortest paths CFN (see S10B Fig) showing links between EGFR and top proteins with dasatinib-inhibited PTMs. Node shape and edge color are defined in S2C Fig. Node size and color represents log2 fold change (bar in A) for all EGFR-mutant cell lines treated with erlotinib (A, C) or dasatinib (B, D).